ClinicalTrials.gg
CompletedNCT03161288Updated Aug 29, 2019

A Study of KY1005 in Healthy Volunteers

A Phase 1 interventional study of KY1005 and Placebo in Immune System Diseases, sponsored by Kymab Limited. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-29.

Sponsored by Kymab Limited (part of Sanofi) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a single and multiple ascending dose, placebo-controlled, double-blind, Phase 1 study to evaluate the safety and tolerability of KY1005 in healthy volunteers.

02

Conditions studied

  • Immune System Diseases
03

In context

Immune System Diseases

428 studies on the registry are indexed under Immune System Diseases; 86 are open to participants now.

This study's enrollment of 64 is close to the median of 66 across 317 interventional studies indexed under Immune System Diseases.

Browse Immune System Diseases studies →

Lead sponsor

Kymab Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.

First submitted before Kymab Limited became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must fulfil all of the following criteria for entry into the study.

  1. Volunteer to participate in the clinical trial and provide signed .
  2. Male, aged 18 to 45 years.
  3. Subjects with a female spouse/partner of must agree to use effective starting at screening and continuing throughout the clinical study period and for a period of up to 6 months after study completion.
  4. Cohorts 4 to 8: previous immunisation with tetanus toxoid (TT) but not within 6 months prior to the screening visit as reported by the volunteer.
  5. Cohorts 4 to 8: anti-TT immunoglobulin G (IgG) response > 0.1 IU/mL and ≤ 50 IU/mL at screening.

Exclusion criteria

Exclusion Criteria:

Subjects fulfilling any of the following exclusion criteria are not eligible for entry into the study.

  1. Experiencing a , chronic or acute infection requiring treatment at screening or prior to first IMP administration.
  2. A body weight of ≤ 60.0 kg or ≥ 120.0 kg.
  3. A ≤ 18.0 or ≥ 30.0 kg/m2.
  4. History of disease of the central nervous system, cardiovascular system, kidney, liver, digestive system, respiratory system or metabolic/endocrine system or suffered from other disease that in the opinion of the principal investigator (or medically qualified designee) may make participation unsafe for the subject or interfere with trial evaluations or otherwise considered clinically significant.
  5. History of immunological abnormality (e.g., immune suppression, severe allergy or anaphylaxis) that in the opinion of the principal investigator (or medically qualified designee) may make participation unsafe for the subject or interfere with trial evaluations or otherwise considered clinically significant.
  6. History of , or known current malignancy.
  7. Leukocyte absolute value \< 3.50 × 10\^9/L or > 9.50 × 10\^9/L, neutrophil absolute value \< 1.8 × 10\^9/L, counts \< 100 × 10\^9/L, \< 12.0 g/dL.
  8. Taken part in other clinical trials within 3 months of screening for this study or > four trials in the year preceding the first IMP administration.
  9. Donated or lost more than 500 mL of blood or plasma within 3 months of screening.
  10. Prescription drug taken within 2 weeks of screening or likely to be taken during the trial.
  11. Live immunisation within 3 months of screening or plans to receive such immunisation during the clinical trial or for a period of 6 months after the end of the trial.
  12. Taking or likely to take over-the-counter medication, including herbal medicines, that in the opinion of the principal investigator (or medically qualified designee) may make participation unsafe for the subject or interfere with trial evaluations.
  13. surface antigen, antibody, or positive.
  14. History of or current drug or substance abuse considered significant by the principal investigator (or medically qualified designee) including a positive urine drug screen.
  15. Current smoker and/or regular user of other nicotine-containing products (e.g., patches).
  16. Average consumption of more than 14 units of alcohol/week.
  17. Clinically significant abnormal screening values in clinical ( (ECGs), vital signs, physical examination) and laboratory tests in the opinion of the principal investigator (or medically qualified designee).
  18. Cannot communicate adequately or cannot commit to full participation in all trial procedures.
  19. For Cohorts 4 to 8:

    1. Confirmed previous exposure to immunocyanins, such as keyhole limpet haemocyanin (KLH);
    2. Known allergy to thiomersal or other components of Tetanus vaccine or Immucothel®;
    3. History of schistosomiasis.
  20. Any observation that, in the opinion of the principal investigator (or medically qualified designee) makes the subject unsuitable for participation in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Cohorts 1-3

    Healthy volunteers will receive single rising doses of KY1005 or placebo

    Drug: KY1005 · Drug: Placebo

  • Experimental
    Cohorts 4-8

    Healthy volunteers will receive multiple rising doses of KY1005 or placebo

    Drug: KY1005 · Drug: Placebo

Interventions

  • DrugKY1005

    A human anti-OX40 ligand monoclonal antibody

  • DrugPlacebo

    Matched placebo

06

What researchers measure

Primary outcomes

  1. Occurrence of all treatment-related adverse events

    Time frame: Cohorts 1 to 3: up to day 113. Cohorts 4 to 8: up to day 92.

  2. Changes in vital signs (as a measure of safety and tolerability)

    Time frame: Cohorts 1 to 3: from pre-first infusion up to day 113. Cohorts 4 to 8: from pre- first infusion up to day 92.

  3. Changes in laboratory safety data (as a measure of safety and tolerability)

    Time frame: Cohorts 1 to 3: from pre-first infusion up to day 113. Cohorts 4 to 8: from pre-first infusion up to day 92.

  4. Changes in anti-viral antibody levels and viral DNA (as a measure of safety and tolerability)

    Time frame: Cohorts 1 to 3: from pre-first infusion up to day 113. Cohorts 4 to 8: from pre-first infusion up to day 92.

  5. Changes in acute cytokines (as a measure of safety and tolerability)

    Time frame: Cohorts 1 to 3: from pre-first infusion up to day 113. Cohorts 4 to 8: from pre-first infusion up to day 92.

  6. Changes in electrocardiograms (as a measure of safety and tolerability)

    Time frame: Cohorts 1 to 3: from pre-first infusion up to day 113. Cohorts 4 to 8: from pre-first infusion up to day 92.

Secondary outcomes

  1. Maximum observed serum concentration (Cmax) following the first, second and third infusions for each KY1005 dose/dosing group

    Time frame: Cohorts 1 to 3: up to day 113. Cohorts 4 to 8: up to day 92.

  2. Time to maximum observed serum concentration (tmax) following the first, second and third infusions for each KY1005 dose/dosing group

    Time frame: Cohorts 1 to 3: up to day 113. Cohorts 4 to 8: up to day 92.

  3. Trough concentrations (Cmin) following the first and second infusions and 28 days after the third infusion

    Time frame: Cohorts 1 to 3: up to day 113. Cohorts 4 to 8: up to day 92.

  4. Areas under the plasma concentration-time curves (AUC)

    Time frame: Cohorts 1 to 3: up to day 113. Cohorts 4 to 8: up to day 92.

  5. Clearance (CL)

    Time frame: Cohorts 1 to 3: up to day 113. Cohorts 4 to 8: up to day 92.

  6. Apparent volume of distribution during terminal phase (Vz)

    Time frame: Cohorts 1 to 3: up to day 113. Cohorts 4 to 8: up to day 92.

  7. Apparent volume of distribution at steady state (Vss)

    Time frame: Cohorts 1 to 3: up to day 113. Cohorts 4 to 8: up to day 92.

  8. Half-life (t½)

    Time frame: Cohorts 1 to 3: up to day 113. Cohorts 4 to 8: up to day 92.

Other outcomes

  1. Serum anti-KY1005 antibody titres

    Change in serum anti-KY1005 antibody titres from pre-infusion.

    Time frame: Cohorts 1 to 3: up to day 113. Cohorts 4 to 8: up to day 92.

  2. Immunophenotype and OX40/OX40L expression

    Changes in specific cell subsets and expression of OX40/OX40L on each subset (where evaluable).

    Time frame: Cohorts 1- 8: up to day 85.

  3. Neo-antigen and recall antigen immunological responses (cohorts 4-8 only)

    Change in anti-tetanus toxoid immunoglobulin G (IgG) and immunoglobulin M (IgM) titres in serum and anti-Immucothel® IgG and IgM titres in serum.

    Time frame: up to day 85

  4. Delayed Type Hypersensitivity response in the skin after intradermal injection of Immucothel® or saline measured by Antera 3D® camera image analysis (cohorts 4-8 only)

    Change in skin colour a and haemoglobin level (concentration of redness per unit area relative to region of interest)

    Time frame: Day 85 and 87

  5. Delayed Type Hypersensitivity response in the skin after intradermal injection of Immucothel® or saline measured by LSCI photography (cohorts 4-8 only)

    Change in basal flow and flare

    Time frame: Day 85 and 87

07

Study locations

1 site
  • Centre for Human Drug Research
    Leiden, Netherlands
08

References and documents

Publications

  • Saghari M, Gal P, Gilbert S, Yateman M, Porter-Brown B, Brennan N, Quaratino S, Wilson R, Grievink HW, Klaassen ES, Bergmann KR, Burggraaf J, van Doorn MBA, Powell J, Moerland M, Rissmann R. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. Clin Pharmacol Ther. 2022 May;111(5):1121-1132. doi: 10.1002/cpt.2539. Epub 2022 Mar 1. PubMed 35092305 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Mar 2018, 10 months.

Of 25 industry-sponsored phase 1 interventional studies under Immune System Diseases, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 32. This study's 10 months is close to that.

Counting every sponsor, half of 39 studies reached it within 29 months; a quarter within 5 and three quarters within 69.

Immune System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2017
First posted
May 19, 2017
StartActual
May 29, 2017
Primary completionActual
Mar 30, 2018
CompletionActual
Mar 30, 2018
Last update
Aug 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03161288
Lead sponsor
Kymab Limited
Responsible party
Sponsor
First posted
May 19, 2017
Start date
May 29, 2017
Primary completion
Mar 30, 2018
Completion
Mar 30, 2018
Last update
Aug 29, 2019

Study contacts

Jacobus Burggraaf
principal investigator · Centre for Human Drug Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion